Literature DB >> 26001218

Fyn-phosphorylated PIKE-A binds and inhibits AMPK signaling, blocking its tumor suppressive activity.

S Zhang1, Q Qi1, C B Chan2, W Zhou3,4, J Chen3,4, H R Luo5, C Appin1, D J Brat1, K Ye1,4.   

Abstract

The AMP-activated protein kinase, a key regulator of energy homeostasis, has a critical role in metabolic disorders and cancers. AMPK is mainly regulated by cellular AMP and phosphorylation by upstream kinases. Here, we show that PIKE-A binds to AMPK and blocks its tumor suppressive actions, which are mediated by tyrosine kinase Fyn. PIKE-A directly interacts with AMPK catalytic alpha subunit and impairs T172 phosphorylation, leading to repression of its kinase activity on the downstream targets. Mutation of Fyn phosphorylation sites on PIKE-A, depletion of Fyn, or pharmacological inhibition of Fyn blunts the association between PIKE-A and AMPK, resulting in loss of its inhibitory effect on AMPK. Cell proliferation and oncogenic assays demonstrate that PIKE-A antagonizes tumor suppressive actions of AMPK. In human glioblastoma samples, PIKE-A expression inversely correlates with the p-AMPK levels, supporting that PIKE-A negatively regulates AMPK activity in cancers. Thus, our findings provide additional layer of molecular regulation of the AMPK signaling pathway in cancer progression.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26001218      PMCID: PMC4815978          DOI: 10.1038/cdd.2015.66

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  42 in total

1.  Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase.

Authors:  S A Hawley; M Davison; A Woods; S P Davies; R K Beri; D Carling; D G Hardie
Journal:  J Biol Chem       Date:  1996-11-01       Impact factor: 5.157

Review 2.  PIKE/nuclear PI 3-kinase signaling in preventing programmed cell death.

Authors:  Keqiang Ye
Journal:  J Cell Biochem       Date:  2005-10-15       Impact factor: 4.429

3.  Pike. A nuclear gtpase that enhances PI3kinase activity and is regulated by protein 4.1N.

Authors:  K Ye; K J Hurt; F Y Wu; M Fang; H R Luo; J J Hong; S Blackshaw; C D Ferris; S H Snyder
Journal:  Cell       Date:  2000-12-08       Impact factor: 41.582

4.  Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase.

Authors:  Simon A Hawley; David A Pan; Kirsty J Mustard; Louise Ross; Jenny Bain; Arthur M Edelman; Bruno G Frenguelli; D Grahame Hardie
Journal:  Cell Metab       Date:  2005-07       Impact factor: 27.287

5.  Phosphoinositol lipids bind to phosphatidylinositol 3 (PI3)-kinase enhancer GTPase and mediate its stimulatory effect on PI3-kinase and Akt signalings.

Authors:  Yuanxin Hu; Zhixue Liu; Keqiang Ye
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-01       Impact factor: 11.205

6.  The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases.

Authors:  Rebecca L Hurley; Kristin A Anderson; Jeanne M Franzone; Bruce E Kemp; Anthony R Means; Lee A Witters
Journal:  J Biol Chem       Date:  2005-06-24       Impact factor: 5.157

7.  The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis.

Authors:  Jiyong Liang; Shan H Shao; Zhi-Xiang Xu; Bryan Hennessy; Zhiyong Ding; Michelle Larrea; Seiji Kondo; Dan J Dumont; Jordan U Gutterman; Cheryl L Walker; Joyce M Slingerland; Gordon B Mills
Journal:  Nat Cell Biol       Date:  2007-01-21       Impact factor: 28.824

8.  Src-family tyrosine kinase fyn phosphorylates phosphatidylinositol 3-kinase enhancer-activating Akt, preventing its apoptotic cleavage and promoting cell survival.

Authors:  X Tang; Y Feng; K Ye
Journal:  Cell Death Differ       Date:  2006-07-14       Impact factor: 15.828

9.  Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells.

Authors:  Angela Woods; Kristina Dickerson; Richard Heath; Seung-Pyo Hong; Milica Momcilovic; Stephen R Johnstone; Marian Carlson; David Carling
Journal:  Cell Metab       Date:  2005-07       Impact factor: 27.287

10.  Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser485/491.

Authors:  Sandrine Horman; Didier Vertommen; Richard Heath; Dietbert Neumann; Véronique Mouton; Angela Woods; Uwe Schlattner; Theo Wallimann; David Carling; Louis Hue; Mark H Rider
Journal:  J Biol Chem       Date:  2005-12-09       Impact factor: 5.157

View more
  12 in total

1.  Tumor Necrosis Factor-α Promotes Phosphoinositide 3-Kinase Enhancer A and AMP-Activated Protein Kinase Interaction to Suppress Lipid Oxidation in Skeletal Muscle.

Authors:  Margaret Chui Ling Tse; Oana Herlea-Pana; Daniel Brobst; Xiuying Yang; John Wood; Xiang Hu; Zhixue Liu; Chi Wai Lee; Aung Moe Zaw; Billy K C Chow; Keqiang Ye; Chi Bun Chan
Journal:  Diabetes       Date:  2017-04-12       Impact factor: 9.461

2.  α-Synuclein binds and sequesters PIKE-L into Lewy bodies, triggering dopaminergic cell death via AMPK hyperactivation.

Authors:  Seong Su Kang; Zhentao Zhang; Xia Liu; Fredric P Manfredsson; Li He; P Michael Iuvone; Xuebing Cao; Yi E Sun; Lingjing Jin; Keqiang Ye
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

3.  Co-amplification of phosphoinositide 3-kinase enhancer A and cyclin-dependent kinase 4 triggers glioblastoma progression.

Authors:  Q Qi; S S Kang; S Zhang; C Pham; H Fu; D J Brat; K Ye
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

4.  Departure from optimal O2 level for mouse trophoblast stem cell proliferation and potency leads to most rapid AMPK activation.

Authors:  Yu Yang; Zhongliang Jiang; Alan Bolnick; Jing Dai; Elizabeth E Puscheck; Daniel A Rappolee
Journal:  J Reprod Dev       Date:  2016-11-18       Impact factor: 2.214

5.  A novel chalcone derivative suppresses melanoma cell growth through targeting Fyn/Stat3 pathway.

Authors:  Ling Tang; Jing Long; Keke Li; Xu Zhang; Xiang Chen; Cong Peng
Journal:  Cancer Cell Int       Date:  2020-06-18       Impact factor: 5.722

6.  SP1 and RARα regulate AGAP2 expression in cancer.

Authors:  Yegor Doush; Arif A Surani; Amaia Navarro-Corcuera; Stephanie McArdle; E Ellen Billett; Cristina Montiel-Duarte
Journal:  Sci Rep       Date:  2019-01-23       Impact factor: 4.379

7.  Fyn tyrosine kinase, a downstream target of receptor tyrosine kinases, modulates antiglioma immune responses.

Authors:  Andrea Comba; Patrick J Dunn; Anna E Argento; Padma Kadiyala; Maria Ventosa; Priti Patel; Daniel B Zamler; Felipe J Núñez; Lili Zhao; Maria G Castro; Pedro R Lowenstein
Journal:  Neuro Oncol       Date:  2020-06-09       Impact factor: 12.300

8.  A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia.

Authors:  Ilaria Laurenzana; Antonella Caivano; Stefania Trino; Luciana De Luca; Francesco La Rocca; Vittorio Simeon; Cristina Tintori; Francesca D'Alessio; Antonella Teramo; Renato Zambello; Antonio Traficante; Maddalena Maietti; Gianpietro Semenzato; Silvia Schenone; Maurizio Botta; Pellegrino Musto; Luigi Del Vecchio
Journal:  Oncotarget       Date:  2016-10-04

9.  Fyn phosphorylates AMPK to inhibit AMPK activity and AMP-dependent activation of autophagy.

Authors:  Eijiro Yamada; Shuichi Okada; Claire C Bastie; Manu Vatish; Yasuyo Nakajima; Ryo Shibusawa; Atsushi Ozawa; Jeffrey E Pessin; Masanobu Yamada
Journal:  Oncotarget       Date:  2016-11-15

10.  FYN promotes gastric cancer metastasis by activating STAT3-mediated epithelial-mesenchymal transition.

Authors:  Jie Yu; ZhiJun Zhou; ZheWei Wei; Jing Wu; Jun OuYang; WeiBin Huang; YuLong He; ChangHua Zhang
Journal:  Transl Oncol       Date:  2020-08-04       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.